MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.03
-0.18
-2.50%
After Hours: 7.03 0 0.00% 16:00 09/20 EDT
OPEN
7.04
PREV CLOSE
7.21
HIGH
7.13
LOW
6.80
VOLUME
192.20K
TURNOVER
--
52 WEEK HIGH
13.49
52 WEEK LOW
6.80
MARKET CAP
238.68M
P/E (TTM)
-8.6672
1D
5D
1M
3M
1Y
5Y
Eiger BioPharmaceuticals Announces Interim Analysis And Continuation Of Dosing Of Peginterferon Lambda In Phase 3 TOGETHER Study Of Newly Diagnosed COVID-19 Outpatients
 Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today
Benzinga · 14h ago
Eiger BioPharmaceuticals Says Data Safety Panel Recommends Continuation of Patient Enrollment for COVID-19 Drug Trial
MT Newswires · 15h ago
Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that , President an...
PR Newswire - PRF · 09/01 20:05
Caxton Corp Buys Rezolute Inc, Addex Therapeutics, Lux Health Tech Acquisition Corp, Sells ...
GuruFocus News · 08/24 16:38
Citigroup Maintains Buy on Eiger BioPharmaceuticals, Raises Price Target to $27
Citigroup analyst Yigal Nochomovitz maintains Eiger BioPharmaceuticals (NASDAQ:EIGR) with a Buy and raises the price target from $26 to $27.
Benzinga · 08/09 12:40
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/05 21:55
Eiger BioPharmaceuticals EPS misses by $0.02, misses on revenue
Eiger BioPharmaceuticals (NASDAQ:EIGR): Q2 GAAP EPS of -$0.57 misses by $0.02. Revenue of $2.09M misses by $0.06M. Cash, cash equivalents, and investments as of June 30, 2021, totaled $139.8M compared
Seekingalpha · 08/05 20:19
Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its second quarter 2...
PR Newswire - PRF · 08/05 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EIGR. Analyze the recent business situations of Eiger through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EIGR stock price target is 29.00 with a high estimate of 45.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 26.59M
% Owned: 78.31%
Shares Outstanding: 33.95M
TypeInstitutionsShares
Increased
35
1.80M
New
9
397.78K
Decreased
26
950.96K
Sold Out
13
1.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
Thomas Dietz
President/Chief Executive Officer/Director
David Cory
Chief Financial Officer
Sriram Ryali
Executive Vice President
Eldon Mayer
Other
James Shaffer
Director
David Apelian
Independent Director
Jeffrey Glenn
Independent Director
Evan Loh
Independent Director
Christine Murray
Independent Director
Kim Sablich
Independent Director
Amit Sachdev
No Data
About EIGR
Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.